Zobrazeno 1 - 10
of 110
pro vyhledávání: '"C. DE VINCI"'
Publikováno v:
Folia biologica. 66(3)
Covid-19 or SARS-CoV-2, a new RNA virus with high infectivity, and seemingly low mutability, which appeared in 2019 in the Wuhan province of China, has created a pandemic with dire consequences. At the end of May 2020, it became the first cause of mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e3501d47383dade4c1420635daf5e00a
https://pubmed.ncbi.nlm.nih.gov/33069187
https://pubmed.ncbi.nlm.nih.gov/33069187
Transfer factor (TF) is a low-molecular-weight lymphocyte extract capable of transferring antigen-specific cell-mediated immunity (CMI) to T lymphocytes. It has been used successfully as an adjuvant or primary therapy for viral, parasitic, fungal, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4094::9c34146b357555ebc33cc9ca5de90c4a
http://hdl.handle.net/11585/141003
http://hdl.handle.net/11585/141003
Autor:
NARDO, BRUNO, BERTELLI, RICCARDO, BELTEMPO, PAOLO, PUVIANI, LORENZA, MONTALTI, ROBERTO, C. De Vinci, V. Pacilè, M. Licursi, A, . Cavallari, G. Pizza
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4094::543f5443b866f3b77f639af9aca1dc62
http://hdl.handle.net/11585/128266
http://hdl.handle.net/11585/128266
Publikováno v:
Folia biologica. 59(2)
Transfer factor (TF) is a low-molecular-weight lymphocyte extract capable of transferring antigen-specific cell-mediated immunity (CMI) to T lymphocytes. It has been used successfully as an adjuvant or primary therapy for viral, parasitic, fungal, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d472f2f8173379f7cb6ee877ac0c6107
https://pubmed.ncbi.nlm.nih.gov/33069186
https://pubmed.ncbi.nlm.nih.gov/33069186
Autor:
D. Menniti, Maver P, P. Romagnoli, Viza D, Riolo U, C De Vinci, A. Palareti, E. Aiello, G. Pizza, Cuzzocrea D, P Zucchelli, V. Fornarola, G. Corrado, Dragoni E, G LoConte
Publikováno v:
Biotherapy. 9:123-132
As conventional treatments are unsuccessful, the survival rate of stage D3 prostate cancer patients is poor. Reports have suggested the existence of humoral and cell-mediated immunity (CMI) against prostate cancer tumour-associated antigens (TAA). Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5036ab14cd23b3918e640e10375b80f0
https://doi.org/10.1007/bf02628669
https://doi.org/10.1007/bf02628669
Autor:
C De Vinci, M L Schiattone, L Rocaccio, L Guerra, M Cicognani, Francesco Gritti, G. Pizza, E. Raise, Viza D
Publikováno v:
Biotherapy. 9:49-54
The efficiency of HIV-1 specific transfer factor (TF) administration, combined with Zidovudine (ZDV), in asymptomatic persistent generalised lymphadenopaty, or AIDS related complex (ARC) patients was evaluated. Twenty patients were randomly assigned
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8711052abb3997cb99451d123d605c7f
https://doi.org/10.1007/bf02628656
https://doi.org/10.1007/bf02628656
Publikováno v:
Folia biologica. 48(5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::35e06d2e60c7debccf143a56b1de4575
https://pubmed.ncbi.nlm.nih.gov/12448765
https://pubmed.ncbi.nlm.nih.gov/12448765
Autor:
G Gozzetti, A. Palareti, L. Busutti, A Cavallari, M. Mastrorilli, V. Pilotti, G. Pizza, C De Vinci
Publikováno v:
Biotherapy (Dordrecht, Netherlands). 9(1-3)
The rationale for using transfer factor (TF) in lung cancer patients is that the possibility of improving their cell-mediated immunity to tumour associated antigens (TAA) may improve their survival. From Jan 1984 to Jan 1995, 99 non-small cell lung c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecbeb1465ee48a3c8528b375297ac340
https://pubmed.ncbi.nlm.nih.gov/8993769
https://pubmed.ncbi.nlm.nih.gov/8993769
Publikováno v:
Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques. 42
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cdda9e425e5a801a4f48d26afc1cd402
https://pubmed.ncbi.nlm.nih.gov/8085013
https://pubmed.ncbi.nlm.nih.gov/8085013
Publikováno v:
Immunotherapy of Renal Cell Carcinoma ISBN: 9783540528357
Our first published data in the immunotherapy of urological cancer with Interleukin- 2 (EL-2) date from 1984 when we observed for the first time tumor regression of infiltrating bladder cancer caused only by the intralesional injection of IL-2 [1].
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec7f50d4d5c47357b2717539a4bf90f5
https://doi.org/10.1007/978-3-642-75853-9_15
https://doi.org/10.1007/978-3-642-75853-9_15